O	0	6	Effect
O	7	9	of
O	10	18	increase
O	19	21	in
O	22	30	duration
O	31	33	of
B-intervention	34	44	aprepitant
O	45	56	consumption
O	57	61	from
O	62	63	3
O	64	66	to
O	67	68	6
O	69	73	days
O	74	76	on
O	77	80	the
O	81	91	prevention
O	92	94	of
B-condition	95	101	nausea
I-condition	102	105	and
I-condition	106	114	vomiting
O	115	117	in
O	118	123	women
O	124	133	receiving
O	134	145	combination
O	146	148	of
O	149	162	anthracycline
O	162	163	/
O	163	179	cyclophosphamide
O	180	192	chemotherapy
O	192	193	:
O	194	195	A
O	196	206	randomized
O	206	207	,
O	208	217	crossover
O	217	218	,
O	219	227	clinical
O	228	233	trial
O	233	234	.

O	235	245	Aprepitant
O	246	248	is
O	249	252	one
O	253	255	of
O	256	259	the
O	260	269	effective
O	270	280	antiemetic
O	281	286	drugs
O	287	291	that
O	292	299	usually
O	300	304	used
O	305	308	for
O	309	310	a
O	311	317	period
O	318	320	of
O	321	322	3
O	323	327	days
O	328	331	for
O	332	342	prevention
O	343	345	of
O	346	359	anthracycline
O	359	360	/
O	360	376	cyclophosphamide
O	377	378	(
O	378	380	AC
O	380	381	)
O	382	389	induced
O	390	396	nausea
O	397	400	and
O	401	409	vomiting
O	409	410	.

O	411	418	However
O	418	419	,
O	420	424	many
O	425	433	patients
O	434	439	still
O	440	450	experience
O	451	457	nausea
O	458	461	and
O	462	470	vomiting
O	471	473	on
O	474	478	days
O	479	480	3
O	480	481	-
O	481	482	5
O	482	483	.

O	484	487	The
O	488	491	aim
O	492	494	of
O	495	499	this
O	500	505	study
O	506	509	was
O	510	512	to
O	513	521	evaluate
O	522	525	the
O	526	532	effect
O	533	535	of
O	536	538	an
O	539	547	increase
O	548	550	in
O	551	559	duration
O	560	562	of
O	563	573	aprepitant
O	574	585	consumption
O	586	590	from
O	591	592	3
O	593	595	to
O	596	597	6
O	598	602	days
O	603	605	on
O	606	609	the
O	610	620	prevention
O	621	623	of
O	624	630	nausea
O	631	634	and
O	635	643	vomiting
O	644	646	in
O	647	652	women
O	653	662	receiving
O	663	665	AC
O	666	678	chemotherapy
O	678	679	.

O	680	682	It
O	683	686	was
O	687	688	a
O	689	699	randomized
O	699	700	,
O	701	710	crossover
O	710	711	,
O	712	722	controlled
O	723	731	clinical
O	732	737	trial
O	737	738	.

B-eligibility	739	744	Women
I-eligibility	745	749	with
I-eligibility	750	756	breast
I-eligibility	757	763	cancer
I-eligibility	764	767	and
I-eligibility	768	777	scheduled
I-eligibility	778	780	to
I-eligibility	781	788	receive
I-eligibility	789	791	AC
I-eligibility	792	800	regimens
O	801	805	were
O	806	814	enrolled
O	815	817	in
O	818	822	this
O	823	828	study
O	828	829	.

O	830	838	Enrolled
O	839	847	patients
O	848	852	were
O	853	863	randomized
O	864	868	into
O	869	872	two
O	873	879	groups
O	879	880	.

O	881	886	Group
O	887	888	I
O	889	897	received
B-control	898	899	3
I-control	900	904	days
I-control	905	912	regimen
I-control	913	915	of
I-control	916	926	aprepitant
O	927	929	in
O	930	933	the
O	934	939	first
O	940	946	course
O	947	949	of
O	950	952	AC
O	953	960	regimen
O	961	973	chemotherapy
O	974	977	and
O	978	979	6
O	980	984	days
O	985	992	regimen
O	993	995	of
O	996	1006	aprepitant
O	1007	1009	in
O	1010	1013	the
O	1014	1020	second
O	1021	1027	course
O	1027	1028	;
O	1029	1034	Group
O	1035	1037	II
O	1038	1046	received
O	1047	1048	6
O	1049	1053	days
O	1054	1061	regimen
O	1062	1070	followed
O	1071	1073	by
O	1074	1075	3
O	1076	1080	days
O	1081	1088	regimen
O	1088	1089	.

O	1090	1093	For
O	1094	1100	nausea
O	1101	1104	and
O	1105	1113	vomiting
O	1114	1124	assessment
O	1124	1125	,
O	1126	1128	we
O	1129	1133	used
O	1134	1141	Eastern
O	1142	1153	Cooperative
O	1154	1162	Oncology
O	1163	1168	Group
O	1169	1182	questionnaire
O	1182	1183	.

B-total-participants	1184	1189	Forty
I-total-participants	1189	1190	-
I-total-participants	1190	1194	nine
O	1195	1203	patients
O	1204	1208	were
O	1209	1217	enrolled
O	1218	1220	in
O	1221	1225	this
O	1226	1231	study
O	1231	1232	.

B-iv-bin-percent	1233	1238	Sixty
I-iv-bin-percent	1238	1239	-
I-iv-bin-percent	1239	1244	three
I-iv-bin-percent	1245	1252	percent
O	1253	1261	achieved
O	1262	1263	a
B-outcome	1264	1272	complete
I-outcome	1273	1281	response
O	1282	1286	with
O	1287	1288	6
O	1289	1293	days
O	1294	1304	aprepitant
O	1305	1312	regimen
O	1313	1321	compared
O	1322	1326	with
B-cv-bin-percent	1327	1329	39
I-cv-bin-percent	1329	1330	%
O	1331	1335	with
O	1336	1337	3
O	1338	1342	days
O	1343	1350	regimen
O	1351	1352	(
O	1352	1353	P
O	1354	1355	<
O	1356	1357	0
O	1357	1358	.
O	1358	1361	001
O	1361	1362	)
O	1362	1363	.

B-iv-bin-percent	1364	1367	Ten
I-iv-bin-percent	1368	1375	percent
O	1376	1379	had
O	1380	1382	at
O	1383	1388	least
O	1389	1392	one
B-outcome	1393	1401	vomiting
I-outcome	1402	1409	episode
O	1410	1416	during
O	1417	1420	the
O	1421	1422	6
O	1423	1427	days
O	1428	1435	regimen
O	1436	1442	versus
B-cv-bin-percent	1443	1445	15
I-cv-bin-percent	1445	1446	%
O	1447	1451	with
O	1452	1453	3
O	1454	1458	days
O	1459	1466	regimen
O	1467	1468	(
O	1468	1469	P
O	1470	1471	=
O	1472	1473	0
O	1473	1474	.
O	1474	1477	034
O	1477	1478	)
O	1478	1479	.

B-outcome	1480	1486	Nausea
O	1487	1490	was
O	1491	1504	significantly
O	1505	1509	more
O	1510	1516	severe
O	1517	1519	in
O	1520	1521	3
O	1522	1526	days
O	1527	1534	regimen
O	1535	1537	of
O	1538	1548	aprepitant
O	1549	1553	than
O	1554	1556	in
O	1557	1558	6
O	1559	1563	days
O	1564	1571	regimen
O	1571	1572	.

O	1573	1581	Increase
O	1582	1584	in
O	1585	1588	the
O	1589	1597	duration
O	1598	1600	of
O	1601	1611	aprepitant
O	1612	1623	consumption
O	1624	1631	through
O	1632	1633	6
O	1634	1638	days
O	1639	1647	resulted
O	1648	1650	in
O	1651	1664	significantly
O	1665	1671	better
O	1672	1682	prevention
O	1683	1685	of
O	1686	1692	nausea
O	1693	1696	and
O	1697	1705	vomiting
O	1706	1710	than
O	1711	1712	3
O	1713	1717	days
O	1718	1729	consumption
O	1730	1733	for
O	1734	1739	women
O	1740	1749	receiving
O	1750	1752	AC
O	1753	1765	chemotherapy
O	1765	1766	.
